Abstract: SA-PO795
Clinical Burden of Native vs. Post-transplant Complement 3 Glomerulopathy (C3G) in the United States: A Retrospective Claims Analysis
Session Information
- C3G, TMA, MGRS, Amyloidosis, and More
October 26, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Ndife, Briana C., Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Bose, Anirban, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Thakkar, Karishma, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Khairnar, Rahul, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Li, Xiaolei, Clarivate, PLC, Toronto, Ontario, Canada
- Young, James B., Clarivate, PLC, Toronto, Ontario, Canada
- Nair, Hemanth, Clarivate, PLC, Toronto, Ontario, Canada
- Narayanan, Mohanram, Baylor Scott & White Medical Center Temple, Temple, Texas, United States
Background
C3G is caused by overactivation of the alternative complement pathway leading to deposition of C3 in the glomeruli. It is a rare disease; its clinical burden has not been well studied. Using medical claims data, this analysis characterized disease progression in a US cohort of patients (pts) with C3G in native kidney (NK) and post-transplant (TK).
Methods
We performed a retrospective cohort analysis of pts ≥12 years of age, diagnosed with C3G (defined by diagnosis codes) within the Clarivate Real-World Data Product database (Jan 2017–Sep 2022). Included pts had database records for ≥12 months (mo) prior to, and ≥6 mo post, the index (date of diagnosis). Pt demographic/clinical characteristics were assessed at index and stratified by transplant status (NK, TK). Time to chronic kidney disease (CKD) progression and/or kidney failure was assessed using Kaplan–Meier analyses.
Results
Of 350 pts with C3G, 244 (69.7%) had NK and 106 (30.3%) had TK; median follow-up was 23.7 mo (interquartile range: 13.9–46.9). Pt characteristics are shown in the Table. The median time to first CKD progression was 13.3 mo (95% confidence interval [CI]: 4.5–28.3) for NK and 3.5 mo (95% CI: 1.0–25.5) for TK. A higher proportion of TK pts (90.9%) progressed to kidney failure vs NK (45.8%). Median time to kidney failure was shorter in pts with TK C3G (27.1 mo [95% CI: 12.2–45.0]) vs NK C3G (43.5 mo [95% CI: 32.9–85.7]).
Conclusion
Disease progression to a higher CKD stage and/or kidney failure is faster in pts with TK C3G compared to pts with NK C3G. Given the disease characteristics and progression, these data highlight the need for novel therapies to treat both NK and TK C3G.
Funding
- Commercial Support – Novartis Pharmaceutical Corporation